← Back to Search

Nonsteroidal Anti-inflammatory Drug

Aspirin for Cardiovascular Disease (CAPE Trial)

Phase 4
Waitlist Available
Led By Kathryn T Hall, PhD
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* healthy, 18-40 years
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at end of treatment 10-14 days the platelets will be activated on the same day as blood collection.
Awards & highlights
Drug Has Already Been Approved
Pivotal Trial
Approved for 10 Other Conditions
All Individual Drugs Already Approved

Summary

This trial will examine the role of genetic variation in COMT on platelet function in a blinded, randomized, placebo controlled clinical trial of daily placebo or Aspirin (81mg) for 10 ± 3 days. Platelet function will be assessed with platelet aggregometry and by fluorescence-activated cell sorting (FACS) of platelet adhesion molecules P-selectin and GPIIb/IIIa in platelets activated with arachidonic acid, thrombin, collagen, epinephrine and ADP.

Eligible Conditions
  • Cardiovascular Disease

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at end of treatment 10-14 days the platelets will be activated on the same day as blood collection.
This trial's timeline: 3 weeks for screening, Varies for treatment, and at end of treatment 10-14 days the platelets will be activated on the same day as blood collection. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
platelet aggregation
Secondary study objectives
% expression of P-selectin on resting and activated platelets

Awards & Highlights

Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: AspirinActive Control1 Intervention
Aspirin (81mg) will be taken orally daily for 10-14 days.
Group II: PlaceboPlacebo Group1 Intervention
Placebo pills that are visually identical to the Aspirin pills will be taken orally, daily for 10-14 days

Find a Location

Who is running the clinical trial?

Brigham and Women's HospitalLead Sponsor
1,666 Previous Clinical Trials
11,840,190 Total Patients Enrolled
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,926 Previous Clinical Trials
47,764,188 Total Patients Enrolled
Kathryn T Hall, PhDPrincipal InvestigatorBrigham and Women's Hospital
~9 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top